bruin cll-322 update: fixed-duration pirtobrutinib plus vr vs vr in patients with r/r cll
Published 1 year ago • 120 plays • Length 1:00Download video MP4
Download video MP3
Similar videos
-
0:50
bruin cll-322: pirtobrutinib plus vr vs vr alone in r/r cll
-
1:56
insights into the bruin cll-322 trial
-
1:43
some insights into bruin cll-322: a trial in progress
-
1:08
pirtobrutinib in cll: updates from the bruin cll-321 trial
-
2:34
bruin study update: analysis of the mechanisms of resistance to pirtobrutinib in cll
-
1:01
pirtobrutinib, venetoclax, and rituximab in the treatment of r/r cll: insights from the bruin trial
-
2:20
genomic evolution and resistance to pirtobrutinib in cll: insights from the bruin study
-
1:27
advances in btk and bcl2 inhibitors for cll
-
4:08
how to resolve daikin vrv lc error |كيفية حل خطأ (lc) دايكن vrv
-
6:29
ac troubleshooting at high floor | error lc | vrv3
-
1:52
how to update fpgbc
-
1:55
update on the phase i/ii bruin study
-
7:55
clinical trials of fixed duration treatments & novel targets in cll
-
3:46
latest updates in the cll treatment landscape
-
1:28
the future of cll treatment
-
2:49
insights into the role of novel btkis in the treatment landscape of r/r cll
-
2:27
update on fixed-duration cohort of captivate trial for cll/sll
-
4:05
comparing continuous and fixed duration therapy in cll
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
1:04
the future of cll therapy
-
3:17
transcend-cll-004 study update: safety and efficacy of liso-cel in r/r cll
-
1:36
improve study update: safety and efficacy of venetoclax retreatment in r/r cll